4.81
price up icon0.21%   +0.010
after-market  After Hours:  4.84  0.03   +0.62%
loading
Immucell Corp. stock is currently priced at $4.81, with a 24-hour trading volume of 27,077. It has seen a +0.21% increased in the last 24 hours and a -4.75% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.83 pivot point. If it approaches the $4.72 support level, significant changes may occur.
Previous Close:
$4.80
Open:
$4.79
24h Volume:
27,077
Market Cap:
$20.10M
Revenue:
$17.47M
Net Income/Loss:
$-5.77M
P/E Ratio:
-6.2468
EPS:
-0.77
Net Cash Flow:
$-6.57M
1W Performance:
-11.58%
1M Performance:
-4.75%
6M Performance:
+1.02%
1Y Performance:
-6.42%
1D Range:
Value
$4.67
$4.95
52W Range:
Value
$4.34
$6.05

Immucell Corp. Stock (ICCC) Company Profile

Name
Name
Immucell Corp.
Name
Phone
207 878 2770
Name
Address
56 Evergreen Drive, Portland, ME
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-06-13
Name
Latest SEC Filings
Name
ICCC's Discussions on Twitter

Immucell Corp. Stock (ICCC) Financials Data

Immucell Corp. (ICCC) Revenue 2024

ICCC reported a revenue (TTM) of $17.47 million for the quarter ending December 31, 2023, a -5.90% decline year-over-year.
loading

Immucell Corp. (ICCC) Net Income 2024

ICCC net income (TTM) was -$5.77 million for the quarter ending December 31, 2023, a -131.56% decrease year-over-year.
loading

Immucell Corp. (ICCC) Cash Flow 2024

ICCC recorded a free cash flow (TTM) of -$6.57 million for the quarter ending December 31, 2023, a -18.98% decrease year-over-year.
loading

Immucell Corp. (ICCC) Earnings per Share 2024

ICCC earnings per share (TTM) was -$0.75 for the quarter ending December 31, 2023, a -141.94% decline year-over-year.
loading
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
$77.56
price up icon 0.77%
$149.40
price down icon 1.20%
$29.98
price up icon 1.11%
$172.85
price up icon 1.06%
$365.81
price down icon 2.87%
$90.61
price down icon 2.55%
Cap:     |  Volume (24h):